These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7851483)

  • 21. Production of immunoreactive insulin-like growth factor I and response to exogenous IGF-I in small cell lung cancer cell lines.
    Jaques G; Rotsch M; Wegmann C; Worsch U; Maasberg M; Havemann K
    Exp Cell Res; 1988 Jun; 176(2):336-43. PubMed ID: 2837402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro effect of suramin on lung tumour cells.
    Mórocz IA; Lauber B; Schmitter D; Stahel RA
    Eur J Cancer; 1993; 29A(2):245-7. PubMed ID: 8422289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours.
    Reeve JG; Payne JA; Bleehen NM
    Br J Cancer; 1990 May; 61(5):727-31. PubMed ID: 1692471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells.
    Sullivan KA; Kim B; Buzdon M; Feldman EL
    Brain Res; 1997 Jan; 744(2):199-206. PubMed ID: 9027379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells.
    Kraft A; Reid LM; Zvibel I
    Cancer Res; 1993 Feb; 53(3):652-7. PubMed ID: 8381048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
    Szereday Z; Schally AV; Varga JL; Kanashiro CA; Hebert F; Armatis P; Groot K; Szepeshazi K; Halmos G; Busto R
    Cancer Res; 2003 Nov; 63(22):7913-9. PubMed ID: 14633721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of breast cancer growth by suramin.
    Vignon F; Prebois C; Rochefort H
    J Natl Cancer Inst; 1992 Jan; 84(1):38-42. PubMed ID: 1738172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth.
    Baghdiguian S; Verrier B; Gerard C; Fantini J
    Cancer Lett; 1992 Feb; 62(1):23-33. PubMed ID: 1311629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines.
    Noll K; Wegmann BR; Havemann K; Jaques G
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2653-62. PubMed ID: 8675593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.
    Marini AM; Fridman R; Kanemoto T; Martin GR; Guo Y; Passaniti A
    J Natl Cancer Inst; 1992 Oct; 84(20):1582-7. PubMed ID: 1328660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of suramin on human lung cancer cell lines.
    Rubio GJ; Pinedo HM; Virizuela J; van Ark-Otte J; Giaccone G
    Eur J Cancer; 1995; 31A(2):244-51. PubMed ID: 7718332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line.
    Kodama Y; Baxter RC; Martin JL
    Am J Respir Cell Mol Biol; 2002 Sep; 27(3):336-44. PubMed ID: 12204896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro.
    Foekens JA; Sieuwerts AM; Stuurman-Smeets EM; Dorssers LC; Berns EM; Klijn JG
    Int J Cancer; 1992 May; 51(3):439-44. PubMed ID: 1592534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Suramin activity in human head and neck squamous cell carcinoma cell lines].
    Li AT
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(2):108-9, 125. PubMed ID: 8217281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures.
    Gansler T; Vaghmar N; Olson JJ; Graham SD
    J Urol; 1992 Sep; 148(3):910-4. PubMed ID: 1512858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemosensitivity testing of human lung cancer cell lines using the MTT assay.
    Carmichael J; Mitchell JB; DeGraff WG; Gamson J; Gazdar AF; Johnson BE; Glatstein E; Minna JD
    Br J Cancer; 1988 Jun; 57(6):540-7. PubMed ID: 2841961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
    Lokshin A; Levitt ML
    J Cell Biochem Suppl; 1996; 24():186-97. PubMed ID: 8806101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
    Kasayama S; Saito H; Kouhara H; Sumitani S; Sato B
    J Cell Physiol; 1993 Feb; 154(2):254-61. PubMed ID: 7678839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.